SCHEMBL22897206

SCHEMBL22897206

Cc1onc(-c2cccs2)c1C(=O)NC(Cc1ccccc1)C(=O)C(N)=O

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HPGDS O60760 3/20 0.50
▸ CAPN1 P07384 8/20 0.46
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ HSPA1A P0DMV8 1/20 0.43
▸ HSPA5 P11021 1/20 0.43
▸ HSPA9 P38646 1/20 0.43
▸ HSPA2 P54652 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ CTSL P07711 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22896355 0.87 L3MBTL1 (0.56) CAPN1MEN1KMT2AALDH1A1MAPK1
SCHEMBL30133620 0.87 L3MBTL1 (0.56) CAPN1MEN1KMT2AALDH1A1MAPK1
SCHEMBL22897110 0.85 HPGDS (0.49) HPGDSCAPN1RAB9AHSPA1AHSPA5
SCHEMBL22897241 0.84 SMN1; SMN2 (0.57) CAPN1MEN1KMT2AALDH1A1MAPK1
SCHEMBL22896794 0.82 CAPN1 (0.48) CAPN1MEN1KMT2AALDH1A1RAB9A
SCHEMBL22897186 0.82 CAPN1 (0.51) CAPN1
SCHEMBL22897034 0.82 CAPN1 (0.49) CAPN1MEN1KMT2AALDH1A1CTSL
SCHEMBL22897259 0.81 L3MBTL1 (0.48) CAPN1MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL22896340 0.81 CAPN1 (0.48) CAPN1MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL22897262 0.81 ALDH1A1 (0.60) CAPN1MEN1KMT2AALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 — — US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 — — US disclosed
US-10894776-B2 — — 2021-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 HPGDS 1604/4885CAPN1 3/4885MEN1 4845/4885
US-10894776-B2 — CAPNS1, CAPN9, CAPN2 HPGDS 1339/4885CAPN1 4/4885MEN1 4832/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 HPGDS 1604/4885CAPN1 3/4885MEN1 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback